Financial PerformanceCDNA shares declined due to a lower-than-expected revenue beat and volume growth, coupled with the absence of full-year guidance reiteration.
Growth ExpectationsManagement's optimistic long-range growth plan of 15% may be unrealistic, creating potential overhang on the stock due to limited upside potential.
Investor ConcernsInvestors may question the realistic growth CDNA can capture from the 'portfolio halo effect' argument, leading to skepticism about future prospects.